The article presents a case study of a young woman admitted to hospital with a 2-day history of decreased consciousness, nausea and vomiting. She was taking valproate for the treatment of temporal lobe epilepsy. On examination it was found that the patient had asterixis, but she had no signs of jaundice and no stigmata of chronic liver disease. The patient was found to have valproate-related hyperammonemic encephalopathy.

The article offers information on a report titled "Valproic acid pharmacogenetics in an individual approach to treatment of women of childbearing age with epilepsy" by N.A. Shnayder and colleagues which appeared in the 2011 issue of the Russian journal.

The article describes the case of a man who developed drug rash with eosinophilia and systemic symptoms syndrome during treatment with carbamazepine for epilepsy. He had a history of epilepsy which was managed with valproic acid and phenobarbital. Due to frequent convulsive episodes,...

OBJECTIVE: To examine a large population with idiopathic generalised epilepsy (IGE), and estimate the overall remission rates for the IGEs and subsyndromes in a clinic based sample. Remission rates on valproate, lamotrigine, topiramate, and combinations of these antiepileptic drugs were...

The article describes the case of a 23-year-old woman who developed coma, metabolic acidosis and hyperammonaemia after ingesting a valproic acid overdose in a suicide attempt. Particular focus is given to the amount of valproic acid ingested by the patient. Her Glasgow Coma Scale score is also...

Valproic acid is effective for treatment of many types of epilepsy, but its use in epileptic patients can be associated with an increase in body weight that could interfere with treatment compliance. The weight gain may result from different mechanisms, but the exact pathogenesis is still...